Compare · ICCC vs ORKA
ICCC vs ORKA
Side-by-side comparison of ImmuCell Corporation (ICCC) and Oruka Therapeutics Inc. (ORKA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ICCC and ORKA operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- ORKA is the larger of the two at $5.56B, about 55.7x ICCC ($99.8M).
- Over the past year, ICCC is up 59.9% and ORKA is up 548.8% - ORKA leads by 488.9 points.
- ORKA has been more active in the news (4 items in the past 4 weeks vs 2 for ICCC).
- ORKA has more recent analyst coverage (11 ratings vs 0 for ICCC).
- Company
- ImmuCell Corporation
- Oruka Therapeutics Inc.
- Price
- $11.00-1.43%
- $92.13+0.21%
- Market cap
- $99.8M
- $5.56B
- 1M return
- +9.73%
- +12.13%
- 1Y return
- +59.88%
- +548.77%
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1987
- News (4w)
- 2
- 4
- Recent ratings
- 0
- 11
ImmuCell Corporation
ImmuCell Corporation, an animal health company, develops, manufactures, and markets products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It offers First Defense, an orally delivered scours preventive product for newborn dairy and beef calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, including a whey protein concentrate for the nutritional and feed supplement markets. In addition, it is involved in developing Re-Tain, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. The company sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.
Latest ICCC
- ImmuCell Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- ImmuCell Announces a 12% Increase in Product Sales in Q2 of 2026 and a 21% Increase in the First Six Months of 2026, Based on Preliminary, Unaudited Sales Results
- President and CEO Te Boekhorst Paul Francis Olivier bought $75,960 worth of shares (8,000 units at $9.49), increasing direct ownership by 82% to 17,785 units (SEC Form 4)
- ImmuCell Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- ImmuCell Corporation filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- ImmuCell Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- SEC Form 10-Q filed by ImmuCell Corporation
- ImmuCell Announces Unaudited Financial Results for the Quarter Ended March 31, 2026
- Amendment: SEC Form 10-K/A filed by ImmuCell Corporation
- ImmuCell Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement
Latest ORKA
- Chief Medical Officer Goncalves Joana exercised 7,000 shares at a strike of $7.32 and sold $603,938 worth of shares (7,000 units at $86.28) as part of a pre-agreed trading plan (SEC Form 4)
- Senior Vice President, Finance Agarwal Arjun exercised 9,999 shares at a strike of $15.69 and sold $846,180 worth of shares (9,999 units at $84.63) as part of a pre-agreed trading plan (SEC Form 4)
- Director Fairmount Funds Management Llc converted options into 3,553,410 shares and sold $300,014,406 worth of shares (3,553,410 units at $84.43) (SEC Form 4)
- Chief Operating Officer Sandler Laura Lee exercised 5,000 shares at a strike of $7.80 and sold $472,079 worth of shares (5,000 units at $94.42) as part of a pre-agreed trading plan (SEC Form 4)
- Senior Vice President, Finance Agarwal Arjun sold $128,468 worth of shares (1,587 units at $80.95) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 15,312 units (SEC Form 4)
- Senior Vice President, Finance Agarwal Arjun exercised 9,459 shares at a strike of $15.88 and sold $687,035 worth of shares (9,854 units at $69.72) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 16,899 units (SEC Form 4) to cover taxes
- Chief Medical Officer Goncalves Joana sold $550,607 worth of shares (7,947 units at $69.28) as part of a pre-agreed trading plan and exercised 7,000 shares at a strike of $7.32, decreasing direct ownership by 3% to 32,718 units (SEC Form 4) (withholding tax)
- Chief Executive Officer Klein Lawrence Otto sold $120,494 worth of shares (1,729 units at $69.69), decreasing direct ownership by 0.19% to 925,580 units (SEC Form 4) to cover taxes
- Chief Operating Officer Sandler Laura Lee sold $41,814 worth of shares (600 units at $69.69), decreasing direct ownership by 0.25% to 236,384 units (SEC Form 4) (for tax liability)
- General Counsel Quinlan Paul T sold $51,083 worth of shares (733 units at $69.69), decreasing direct ownership by 2% to 31,034 units (SEC Form 4) (for withholding tax)